<- Go Home
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Market Cap
$202.7M
Volume
238.0K
Cash and Equivalents
$25.7M
EBITDA
-$89.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$70.1M
Profit Margin
N/A
52 Week High
$20.56
52 Week Low
$6.72
Dividend
N/A
Price / Book Value
1.60
Price / Earnings
-2.02
Price / Tangible Book Value
1.60
Enterprise Value
$65.7M
Enterprise Value / EBITDA
-0.75
Operating Income
-$89.8M
Return on Equity
66.70%
Return on Assets
-39.48
Cash and Short Term Investments
$138.2M
Debt
$1.2M
Equity
$126.3M
Revenue
N/A
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A